Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Growth hormone safety update from the National Cooperative Growth Study
Autore:
Maneatis, T; Baptista, J; Connelly, K; Blethen, S;
Indirizzi:
Genentech Inc, Drug Safety, S San Francisco, CA 94080 USA Genentech Inc SSan Francisco CA USA 94080 S San Francisco, CA 94080 USA Genentech Inc, Dept Med Affairs, S San Francisco, CA 94080 USA Genentech Inc S San Francisco CA USA 94080 S San Francisco, CA 94080 USA
Titolo Testata:
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
, volume: 13, anno: 2000, supplemento:, 2
pagine: 1035 - 1044
SICI:
0334-018X(200009)13:<1035:GHSUFT>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
BENIGN INTRACRANIAL HYPERTENSION; TUMOR RECURRENCE; TREATED PATIENTS; INCREASED RISK; CHILDREN; LEUKEMIA; EXPERIENCE; THERAPY;
Keywords:
leukemia; nonleukemic malignancy; brain tumor recurrence; intracranial hypertension; diabetes mellitus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Maneatis, T Genentech Inc, Drug Safety, 1 DNA Way, S San Francisco, CA 94080 USA Genentech Inc 1 DNA Way S San Francisco CA USA 94080 94080 USA
Citazione:
T. Maneatis et al., "Growth hormone safety update from the National Cooperative Growth Study", J PED END M, 13, 2000, pp. 1035-1044

Abstract

We reviewed adverse event (AE) data in the National Cooperative Growth Study from startup (1985) until January 1, 1999, Enrollment was 33,161, A total of 2,632 AE reports were received; 863 were serious events, with 156 deaths. The most common cause of death was recurrence of intracranial neoplasm,There were 20 reports of leukemia, and the standard morbidity ratio (SMR) was 0.73 (95% CI: 0.20-1.86) for the four cases without risk factors, Therewere 35 reports of extracranial nonleukemic malignancy, and the SMR was 0.44 (95% CI: 0.24-0.74) for the 14 cases without risk factors. The recurrence rate for all brain tumors present at baseline was 7.6%, and for craniopharyngiomas, 6.4%, There were 49 reports of intracranial hypertension (20 patients had papilledema), 68 reports of diabetes/hyperglycemia, 45 of slippedcapital femoral epiphysis, 136 of scoliosis, and five of pancreatitis,There was no evidence of increased incidence of leukemia or extracranial nonleukemic malignancies among patients without prior risk factors. Intracranial hypertension does not necessarily occur early in growth hormone therapy. Other findings were consistent with past observations.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 19:02:07